Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us prof. dr. T. van Meerten
University Medical Center Groningen

prof. dr. T. van Meerten

No picture available
E-mail:
t.van.meerten umcg.nl

Publications

Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL

Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study

Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy: LYMPHOMA

Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Facts and hopes for PET imaging-derived immunotherapy biomarkers

Press/media

Je eigen bloedcellen als medicijn tegen een auto-immuunziekte of bloedkanker

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness

Subsidie voor onderzoek CAR-T-cellen voor mensen met multipel myeloom

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Gronings UMC gaat met overheidssubsidie zelf een prijzig buitenlands kankermedicijn maken

16,5 miljoen subsidie voor onderzoek CAR T-cellen bij beenmergkanker

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: 'Je wint tijd'